US Bancorp DE Sells 59,755 Shares of Edwards Lifesciences Co. (NYSE:EW)

US Bancorp DE lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 647,976 shares of the medical research company’s stock after selling 59,755 shares during the period. US Bancorp DE owned about 0.11% of Edwards Lifesciences worth $47,970,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. Abacus Planning Group Inc. increased its position in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after buying an additional 140 shares in the last quarter. Bowman & Co S.C. grew its stake in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares during the period. Pegasus Asset Management Inc. increased its holdings in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after acquiring an additional 159 shares in the last quarter. Mount Yale Investment Advisors LLC raised its position in shares of Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after purchasing an additional 162 shares during the period. Finally, JFS Wealth Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on EW. Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Citigroup increased their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.95.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock worth $2,799,104 over the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.3 %

Shares of EW stock opened at $71.61 on Friday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market cap of $42.24 billion, a price-to-earnings ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.10. The firm’s 50-day moving average is $72.64 and its 200-day moving average is $70.27.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.